Igor Vujic
Vienna, 1030, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia.
Journal: EMBO molecular medicine
Published: June 12, 2024
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Journal: Molecular cancer
Published: January 02, 2024
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Journal: Research square
Published: December 11, 2023
Systemic IFN-I combined with topical TLR7/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells.
Journal: Nature cancer
Published: September 18, 2023
Corrigendum: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV).
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 13, 2023
Entwicklung der Patientencharakteristika und der Wirksamkeit der Biologika-Therapie bei Patienten des Österreichischen Psoriasis-Registers von 2004 bis 2022.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: January 22, 2023
Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: January 22, 2023
S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV).
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 27, 2022
Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study.
Journal: Therapeutic advances in chronic disease
Published: September 16, 2022
Melanoma risk during immunomodulating treatment.
Journal: Melanoma research
Published: August 22, 2022
Apremilast bei oralem Lichen planus - eine multizentrische, retrospektive Studie.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: March 19, 2022
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 13, 2022
Last Updated: 09/26/2026